inhabitants-000-number-50.html
DANMAP 2015 3D
51 / 144
51 danmap
2015
5. antimicrobial consumption
in humans such changes in did that are not reflected in the number of prescriptions and vice versa probably reflect alterations in consumption within the same antimicrobial class. for instance there may be increases in ddd according to new treatment recommendations or clinical guidelines - this happens when the dosage or the daily intake increases (e.g from 200mg to 400mg per dosage or from three to four times daily). a concurrent decrease in ddds may be caused by changes in the recommended treatment duration (e.g.from seven days treatment to five days). finally, changes in the application or preference of the different drugs may change over time ? for instance, when a specific drug is used for infections other than the primary indication. table 5.4 shows the total consumption of antimicrobial classes at a regional level for the last five years, 2011 to 2015. all five regions show decreases for both the ddd per 1,000 inhabitants
per day and for the number of prescriptions per 1,000 inhabitants per day. in 2015 the region of zealand had the highest consumption, when measured in ddd per 1,000 inhabitants per day, while the central denmark region and the northern denmark region had the lowest consumption, 16.9 did and 15.2 did, respectively. the region zealand had 0 100 200 300 400 500 600 700 5000 5200 5400 5600 5800 6000 6200 6400 6600 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 prescriptions/users/1000 inhabitants ddd/1000 inhabitants ddd/1000 inhabitants prescriptions/1000 inhabitants users/1000 inhabitants fig 5.5 figure 5.5. indicators of antimicrobial consumption (j01) in primary health care, denmark danmap 2015 table 5.3. number of prescriptions per 1,000 inhabitants for leading antimicrobial agents in primary health care, denmark atc group (a) therapeutic group year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 j01aa tetracyclines 12.25 12.52 12.73 13.02 13.44 13.66 13.53 13.85 12.20 11.32 j01ca penicillins with extended spectrum 75.78 82.03 81.27 81.07 85.04 84.19 77.29 76.09 75.32 74.88 j01ce beta-lactamase sensitive penicillins 171.29 177.07 164.38 158.72 162.81 164.34 145.50 142.16 134.79 130.07 j01cf beta-lactamase resistant penicillins 29.38 29.67 29.89 29.87 30.02 30.34 28.50 29.07 29.24 28.85 j01cr combinations of penicillins, including beta-lactamase inhibitors 2.27 3.57 4.95 8.02 11.70 14.95 17.34 19.71 20.52 22.03 j01e sulphonamides and trimethoprim 36.56 33.62 30.49 29.51 29.31 27.63 26.47 26.15 24.65 22.45 j01fa macrolides 67.03 71.38 66.84 64.44 72.67 78.75 64.72 56.15 51.38 51.75 j01ma fluoroquinolones 13.09 15.19 17.05 16.87 18.45 18.10 17.24 16.04 15.30 15.04 j01xx other antibacterials (methenamine >99%) 7.70 7.17 7.43 7.67 7.53 7.74 7.54 7.48 7.16 7.35 j01xd and p01ab nitroimidazole derivatives (metronidazole) 13.77 14.44 15.32 16.28 16.73 16.90 16.86 16.51 16.31 16.47 j01 (incl. p01) antibacterial agents for systemic use (total) 603.60 630.08 606.26 595.28 628.78 638.08 582.69 565.16 542.53 530.62 danmap 2015
penicillins-consumption-did-52.html
